Affimed NV (NASDAQ:AFMD) – Analysts at Jefferies Financial Group lifted their Q4 2019 earnings per share estimates for Affimed in a report issued on Thursday, May 23rd. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will earn $0.58 per share for the quarter, up from their previous forecast of $0.53. Jefferies Financial Group also issued estimates for Affimed’s FY2020 earnings at $0.91 EPS.
Affimed (NASDAQ:AFMD) last announced its quarterly earnings results on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.19. The business had revenue of $12.89 million during the quarter, compared to analysts’ expectations of $6.77 million. Affimed had a negative net margin of 87.00% and a negative return on equity of 44.56%.
AFMD has been the subject of a number of other research reports. Leerink Swann began coverage on shares of Affimed in a report on Thursday, March 28th. They issued an “outperform” rating and a $4.17 price objective for the company. ValuEngine cut shares of Affimed from a “buy” rating to a “hold” rating in a report on Friday, March 29th. Zacks Investment Research upgraded shares of Affimed from a “hold” rating to a “strong-buy” rating and set a $4.75 price objective for the company in a report on Friday, March 29th. Finally, Svb Leerink began coverage on shares of Affimed in a report on Thursday, March 28th. They issued an “outperform” rating and a $8.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Affimed presently has an average rating of “Buy” and an average target price of $4.99.
Shares of AFMD stock opened at $3.10 on Monday. The company has a quick ratio of 3.00, a current ratio of 3.01 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $193.41 million, a P/E ratio of -8.16 and a beta of 3.23. Affimed has a fifty-two week low of $1.40 and a fifty-two week high of $7.35.
Several hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its position in Affimed by 7.1% during the first quarter. Wells Fargo & Company MN now owns 145,451 shares of the biopharmaceutical company’s stock valued at $611,000 after buying an additional 9,693 shares during the period. Bourgeon Capital Management LLC acquired a new stake in Affimed during the first quarter valued at $42,000. CIBC World Markets Inc. grew its position in Affimed by 17.7% during the first quarter. CIBC World Markets Inc. now owns 66,500 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 10,000 shares during the period. Sigma Planning Corp acquired a new stake in Affimed during the first quarter valued at $46,000. Finally, D. E. Shaw & Co. Inc. acquired a new stake in Affimed during the fourth quarter valued at $36,000. Hedge funds and other institutional investors own 40.90% of the company’s stock.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
See Also: What does EPS mean?
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.